An evaluation of estramustine, docetaxel and zoledronate [zoledronic acid] in patients with hormone-refractory adenocarcinoma of the prostate

Trial Profile

An evaluation of estramustine, docetaxel and zoledronate [zoledronic acid] in patients with hormone-refractory adenocarcinoma of the prostate

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jan 2015

At a glance

  • Drugs Zoledronic acid (Primary) ; Docetaxel; Estramustine
  • Indications Prostate cancer
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 26 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top